Gilead Sciences | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.25B 40M 2025-06
Agios Pharmaceuticals USD 45.87M 4.34M 2025-06
ALKERMES USD 153.87M 17.83M 2025-06
Alnylam Pharmaceuticals USD 323.31M 83.36M 2025-06
Amgen USD 1.69B 191M 2025-03
Biogen USD 583.8M 11.3M 2025-06
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Bristol-Myers Squibb USD 1.71B 129M 2025-06
Eli Lilly USD 2.36B 62.3M 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
GlaxoSmithKline GBP 2.14B 80M 2025-06
Glaxosmithkline GBP 2.7B 632M 2024-12
Incyte USD 331.02M 5.33M 2025-06
J&J USD 5.89B 777M 2025-06
Merck USD 2.63B 104M 2025-06
Moderna USD 230M 18M 2025-06
Neurocrine Biosciences USD 286.3M 9.8M 2025-06
Novartis USD 3.44B 384M 2025-06
Pfizer USD 3.01B 1.27B 2025-03
PTC Therapeutics USD 161.92M 77.24M 2025-03
Regeneron Pharmaceuticals USD 634.2M 1.2M 2025-06
Sanofi EUR 2.63B 408M 2025-06
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
United Therapeutics USD 212.5M 42.4M 2025-06
Vertex Pharmaceuticals USD 424.6M 28.2M 2025-06


Gilead Sciences Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Aug 2025.